ARK Invest
SuperinvestorARK Investment Management LLC
- SEC CIK
- 0001697748
- Manager
- Cathie Wood
- Style
- Growth
- Latest filing
- Aug 14, 2026
CRSP holding history
CRISPR Therapeutics AG in every 13F filed by ARK Invest, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CRSP overviewAll 13F holders of CRSPFull Q2 2026 holdings
- Shares (Q2 2026)
- 9,460,939
- Value
- $516.0M
- % of portfolio
- 3.4%
- Quarters held
- 22
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 9,460,939 | $516.0M | 3.4% | −1,852,684−16.4% | Reduced | Holders |
| Q1 2026 | 11,313,623 | $538.2M | 4.2% | +791,566+7.5% | Added | Holders |
| Q4 2025 | 10,522,057 | $551.8M | 3.7% | +735,084+7.5% | Added | Holders |
| Q3 2025 | 9,786,973 | $634.3M | 3.8% | −395,617−3.9% | Reduced | Holders |
| Q2 2025 | 10,182,590 | $495.3M | 3.6% | +17,190+0.2% | Added | Holders |
| Q1 2025 | 10,165,400 | $345.9M | 3.5% | +1,192,336+13.3% | Added | Holders |
| Q4 2024 | 8,973,064 | $353.2M | 2.9% | +1,474,439+19.7% | Added | Holders |
| Q3 2024 | 7,498,625 | $352.3M | 3.2% | −279,911−3.6% | Reduced | Holders |
| Q2 2024 | 7,778,536 | $420.1M | 3.7% | −378,492−4.6% | Reduced | Holders |
| Q1 2024 | 8,157,028 | $556.0M | 3.8% | −379,076−4.4% | Reduced | Holders |
| Q4 2023 | 8,536,104 | $534.4M | 3.2% | +1,372,986+19.2% | Added | Holders |
| Q3 2023 | 7,163,118 | $325.1M | 2.5% | −175,329−2.4% | Reduced | Holders |
| Q2 2023 | 7,338,447 | $412.0M | 2.7% | −651,741−8.2% | Reduced | Holders |
| Q1 2023 | 7,990,188 | $361.4M | 2.5% | +160,256+2.0% | Added | Holders |
| Q4 2022 | 7,829,932 | $318.3M | 2.8% | −407,190−4.9% | Reduced | Holders |
| Q3 2022 | 8,237,122 | $538.3M | 3.8% | −1,490,409−15.3% | Reduced | Holders |
| Q2 2022 | 9,727,531 | $564.7M | 3.4% | +323,460+3.4% | Added | Holders |
| Q1 2022 | 9,404,071 | $590.3M | 2.5% | +316,203+3.5% | Added | Holders |
| Q4 2021 | 9,087,868 | $688.7M | 2.1% | +1,502,194+19.8% | Added | Holders |
| Q3 2021 | 7,585,674 | $849.1M | 2.0% | −190,445−2.4% | Reduced | Holders |
| Q2 2021 | 7,776,119 | $1.26B | 2.3% | −514,231−6.2% | Reduced | Holders |
| Q1 2021 | 8,290,350 | $1.01B | 2.0% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.